Legal & General Group Plc Makes New $4.64 Million Investment in Pediatrix Medical Group, Inc. $MD

Legal & General Group Plc acquired a new stake in Pediatrix Medical Group, Inc. (NYSE:MD) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 183,099 shares of the company’s stock, valued at approximately $4,638,000.

Several other hedge funds have also recently modified their holdings of the company. Global Retirement Partners LLC bought a new position in shares of Pediatrix Medical Group in the second quarter valued at approximately $33,000. Transamerica Financial Advisors LLC purchased a new position in Pediatrix Medical Group in the fourth quarter worth $30,000. Eurizon Capital SGR S.p.A. bought a new position in Pediatrix Medical Group in the 4th quarter valued at $33,000. TD Private Client Wealth LLC purchased a new stake in shares of Pediatrix Medical Group during the 4th quarter valued at $39,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Pediatrix Medical Group during the 4th quarter valued at $43,000. Institutional investors own 97.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. UBS Group boosted their price target on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $25.00 price target on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. Weiss Ratings lowered Pediatrix Medical Group from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 25th. Jefferies Financial Group downgraded Pediatrix Medical Group from a “buy” rating to a “hold” rating and raised their target price for the stock from $27.00 to $28.00 in a research report on Wednesday, August 19th. Finally, Mizuho set a $24.00 target price on Pediatrix Medical Group in a research note on Friday, May 8th. Seven analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $25.00.

Pediatrix Medical Group Price Performance

Pediatrix Medical Group stock opened at $26.89 on Friday. The firm has a market capitalization of $2.18 billion, a P/E ratio of 12.87 and a beta of 0.64. Pediatrix Medical Group, Inc. has a one year low of $15.69 and a one year high of $27.94. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.32 and a quick ratio of 1.32. The business has a fifty day moving average price of $26.27 and a 200-day moving average price of $23.34.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The company had revenue of $487.78 million for the quarter, compared to analyst estimates of $478.49 million. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.53 EPS. As a group, equities research analysts forecast that Pediatrix Medical Group, Inc. will post 2.17 EPS for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.